

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2023

	Shares	Value
COMMON STOCKS[†] - 99.5%		
Biotechnology - 74.6%		
Amgen, Inc.	22,947	\$ 6,609,195
Vertex Pharmaceuticals, Inc.*	11,916	4,848,501
Regeneron Pharmaceuticals, Inc.*	5,420	4,760,332
Gilead Sciences, Inc.	58,422	4,732,766
Moderna, Inc.*	33,946	3,375,930
Biogen, Inc.*	12,718	3,291,037
Corteva, Inc.	64,623	3,096,734
Illumina, Inc.*	18,813	2,619,522
Alnylam Pharmaceuticals, Inc.*	13,656	2,613,895
Cytokinetics, Inc.*	27,323	2,281,197
BioMarin Pharmaceutical, Inc.*	23,095	2,226,820
Royalty Pharma plc — Class A	68,419	1,921,890
Incyte Corp.*	30,192	1,895,756
Legend Biotech Corp. ADR*	28,526	1,716,409
United Therapeutics Corp.*	7,160	1,574,412
Sarepta Therapeutics, Inc.*	16,261	1,568,048
ImmunoGen, Inc.*	49,427	1,465,511
Exelixis, Inc.*	60,869	1,460,247
Intra-Cellular Therapies, Inc.*	19,815	1,419,150
Ionis Pharmaceuticals, Inc.*	27,460	1,389,201
BioNTech SE ADR*	12,391	1,307,746
Bridgebio Pharma, Inc.*	31,868	1,286,511
Karuna Therapeutics, Inc.*	4,028	1,274,902
Roivant Sciences Ltd.*	110,138	1,236,850
ACADIA Pharmaceuticals, Inc.*	38,459	1,204,151
Blueprint Medicines Corp.*	13,045	1,203,271
Apellis Pharmaceuticals, Inc.*	20,005	1,197,499
Argenx SE ADR*	3,121	1,187,322
REVOLUTION Medicines, Inc.*	41,096	1,178,633
CRISPR Therapeutics AG*	18,697	1,170,432
Amicus Therapeutics, Inc.*	82,424	1,169,597
Insmed, Inc.*	37,152	1,151,341
Halozyne Therapeutics, Inc.*	29,464	1,088,990
Ultragenyx Pharmaceutical, Inc.*	22,494	1,075,663
Arrowhead Pharmaceuticals, Inc.*	33,819	1,034,861
Mirati Therapeutics, Inc.*	17,168	1,008,620
Guardant Health, Inc.*	34,283	927,355
Immunovant, Inc.*	20,363	857,893
Intellia Therapeutics, Inc.*	27,798	847,561
Axsome Therapeutics, Inc.*	10,113	804,894
TG Therapeutics, Inc.*	47,043	803,495
Iovance Biotherapeutics, Inc.*	95,480	776,252
PTC Therapeutics, Inc.*	27,608	760,877
Prothena Corporation plc*	20,627	749,585
Dynavax Technologies Corp.*	50,798	710,156
Beam Therapeutics, Inc.* ¹	24,560	668,523
Akero Therapeutics, Inc.*	26,132	610,182
Krystal Biotech, Inc.*	4,629	574,274
Sage Therapeutics, Inc.*	26,068	564,894
Novavax, Inc.*	74,642	358,282
Total Biotechnology		83,657,165
Pharmaceuticals - 18.6%		
AbbVie, Inc.	56,397	8,739,843
AstraZeneca plc ADR	43,595	2,936,123
Viatis, Inc.	180,371	1,953,418
Neurocrine Biosciences, Inc.*	14,605	1,924,355
Alkermes plc*	55,142	1,529,639
Jazz Pharmaceuticals plc*	11,642	1,431,966
Vaxcyte, Inc.*	18,581	1,166,887
Ironwood Pharmaceuticals, Inc. — Class A*	59,223	677,511
Madrigal Pharmaceuticals, Inc.*	2,447	566,187
Total Pharmaceuticals		20,925,929
Healthcare-Products - 5.2%		
Exact Sciences Corp.*	27,239	2,015,141
Natera, Inc.*	22,863	1,432,138
Novocure Ltd.*	95,849	1,431,026
Pacific Biosciences of California, Inc.*	92,643	908,828
Total Healthcare-Products		5,787,133
Healthcare-Services - 1.1%		
Medpace Holdings, Inc.*	4,208	1,289,879
Total Common Stocks (Cost \$57,286,458)		111,660,106
	Face Amount	
REPURCHASE AGREEMENTS^{††,2} - 0.2%		
J.P. Morgan Securities LLC issued 12/29/23 at 5.33% due 01/02/24	\$ 126,182	126,182
BofA Securities, Inc. issued 12/29/23 at 5.35% due 01/02/24	101,689	101,689
Total Repurchase Agreements (Cost \$227,871)		227,871
	Shares	
SECURITIES LENDING COLLATERAL^{†,3} - 0.5%		
Money Market Fund		
First American Government Obligations Fund - Class X, 5.29% ⁴	565,545	565,545
Total Securities Lending Collateral (Cost \$565,545)		565,545
Total Investments - 100.2% (Cost \$58,079,874)		\$ 112,453,522
Other Assets & Liabilities, net - (0.2)%		(255,578)

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at December 31, 2023.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of December 31, 2023.

ADR — American Depositary Receipt
plc — Public Limited Company